About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Maybe We Should Make It More of a Game | Main | If You're Not A Chemist - What Next? »

August 10, 2010

All Quiet on the Genzyme Front?

Email This Entry

Posted by Derek

Notice how quiet it's gotten on the Sanofi-Aventis / Genzyme story? News of the preliminary discussions leaked, then for the first few days we had constant reports from "people familiar with the negotiations". Now, zilch.

It's enough to make me think that someone tracked down the person (or persons) responsible for all the chatter and gave them some good reasons to be quiet. We'll see if the flow of gossip resumes or not. . .

Comments (6) + TrackBacks (0) | Category: Business and Markets


1. anon on August 10, 2010 10:16 AM writes...

Simply, part of the courtship. The dance is on.

Permalink to Comment

2. Recovering Analyst on August 10, 2010 10:37 AM writes...

I'm in biz dev - for an acquisition of this magnitude, only the most senior people in both companies would know about the proposed transaction, so anything "leaked" would have been done on purpose. I doubt these senior persons in the know would have been muzzled. It's quite possible that absolutely nothing is happening or there's nothing new in the discussions. It also might indicate that after all the initial posturing, they're moving into serious discussions, possibly even doing due diligence. My guess is that even with the high profile nature of this acquisition, we won't see anything definitive for at least 2 months - it takes a long time and a lot of work to do proper due diligence on someone as big as Genzyme.

Permalink to Comment

3. Data Police on August 10, 2010 11:29 AM writes...

I think most of it is coming from activist investors

Permalink to Comment

4. Hap on August 10, 2010 12:25 PM writes...

Wouldn't activist investors be looking to leak more though? Silence probably isn't in their best interest, but a feeding frenzy probably is.

Perhaps they're trying to keep their upper management quiet - the frenzy might help, by raising the value of their stock, but since management might be out on the street afterwards, some might have reason to try to torpedo the deal. The company has more leverage against its employees than its investors, as well.

Permalink to Comment

5. Anonymous on August 10, 2010 2:16 PM writes...


"....but since management might be out on the street afterwards, some might have reason to try to torpedo the deal."

Genzyme's CEO gets a $22 million 'change-of-control' payment if the deal goes through. All the other top guys are getting about $5-6 million each.

Perhaps I'm naive but I don't think the employees or shareholders of Genzyme should count on the management worrying about incremental changes in stock price to influence their actions at this juncture.

Permalink to Comment

6. Denise on August 10, 2010 3:47 PM writes...

It is vacation time in France....

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry